Greg R Angstreich, MD | |
520 Superior Ave, Suite 300, Newport Beach, CA 92663-3637 | |
(949) 646-6441 | |
(949) 646-5719 |
Full Name | Greg R Angstreich |
---|---|
Gender | Male |
Speciality | Hematology/oncology |
Experience | 27 Years |
Location | 520 Superior Ave, Newport Beach, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659303873 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | C54662 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hoag Memorial Hospital Presbyterian | Newport beach, CA | Hospital |
Keck Hospital Of Usc | Los angeles, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Usc Care Medical Group Inc | 0446157747 | 1128 |
News Archive
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers at The University of Texas Health Science Center at Houston are sharing critical health information through an atypical venue: the emergency room.
Now that the Supreme Court has remanded Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. (AMP v. Myriad) to the Court of Appeals for the Federal Circuit for further consideration, AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company's I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.
New research shows that patients have a much better chance of survival when both their hospital and their physician have a strong track record in treating heart attack with angioplasty and stenting.
› Verified 2 days ago
Entity Name | Usc Care Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1902846306 PECOS PAC ID: 0446157747 Enrollment ID: O20050512000412 |
News Archive
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers at The University of Texas Health Science Center at Houston are sharing critical health information through an atypical venue: the emergency room.
Now that the Supreme Court has remanded Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. (AMP v. Myriad) to the Court of Appeals for the Federal Circuit for further consideration, AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company's I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.
New research shows that patients have a much better chance of survival when both their hospital and their physician have a strong track record in treating heart attack with angioplasty and stenting.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Greg R Angstreich, MD Po Box 31309, Los Angeles, CA 90031-0309 Ph: (949) 646-6441 | Greg R Angstreich, MD 520 Superior Ave, Suite 300, Newport Beach, CA 92663-3637 Ph: (949) 646-6441 |
News Archive
Researchers open the way for improved study of hepatitis C virus by devising a novel virus culture system that allows replication of patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus strains in transformed cell lines.
With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers at The University of Texas Health Science Center at Houston are sharing critical health information through an atypical venue: the emergency room.
Now that the Supreme Court has remanded Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. (AMP v. Myriad) to the Court of Appeals for the Federal Circuit for further consideration, AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company's I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.
New research shows that patients have a much better chance of survival when both their hospital and their physician have a strong track record in treating heart attack with angioplasty and stenting.
› Verified 2 days ago
Dr. Sevitlana Safaei, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 520 Superior Ave, Ste 205, Newport Beach, CA 92663 Phone: 949-650-2462 Fax: 949-650-1366 | |
Dr. Jin-hwa Simon, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Hoag Dr, Newport Beach, CA 92663 Phone: 949-610-7245 Fax: 657-241-7720 | |
Brian Kong, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Hoag Dr, Newport Beach, CA 92663 Phone: 949-610-7245 Fax: 657-241-7720 | |
Dr. Cesar Balbin Guerrero, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 350 Vista Madera, Newport Beach, CA 92660 Phone: 949-270-6371 | |
Nhat Tran, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Hoag Dr, Newport Beach, CA 92663 Phone: 949-610-7245 Fax: 657-241-7720 | |
Dr. Leslie Kennerly Meserve, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 400 Newport Center Dr Ste 310, Newport Beach, CA 92660 Phone: 949-558-0501 Fax: 949-558-0502 | |
Bhavini Jashvant Jaiswal, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Hoag Dr, Critical Care Department Box 6100, Newport Beach, CA 92663 Phone: 480-227-1318 |